MARKET

CANF

CANF

CAN FITE BIOPHAR
AMEX

Real-time Quotes | Nasdaq Last Sale

1.740
0.000
0.00%
Closed 16:00 09/17 EDT
OPEN
1.730
PREV CLOSE
1.740
HIGH
1.750
LOW
1.710
VOLUME
56.96K
TURNOVER
--
52 WEEK HIGH
4.390
52 WEEK LOW
1.640
MARKET CAP
33.22M
P/E (TTM)
-2.4576
1D
5D
1M
3M
1Y
5Y
Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
PETACH TIKVA, Israel, September 17, 2021--Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
Business Wire · 14h ago
Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
PETACH TIKVA, Israel, September 09, 2021--Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Business Wire · 09/09 11:00
BRIEF-Can-Fite Completes Patient Enrollment In Phase Iii Psoriasis Study
reuters.com · 09/02 11:36
Can-Fite Reports Completion Of Patient Enrollment In Phase 3 Psoriasis Study; Topline Results Expected In Q1'22
Positive interim analysis data was released in October 2020 based on results from 200 patients Topline results expected Q1 2022 PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE:CANF)
Benzinga · 09/02 11:04
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
PETACH TIKVA, Israel, September 02, 2021--Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
Business Wire · 09/02 11:00
Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY
Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021.
Benzinga · 08/26 16:48
Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended June ...
Business Wire · 08/26 11:00
HVBT, PSTI and DPW among pre market gainers
Enlivex Therapeutics ENLV +22% to launch Phase IIb Allocetra trial for COVID-19 patients in Israel ADMA Biologics ADMA +17% on FDA approval for plasma collection facility in Maryville, TN Travere Therapeutics TVTX +17% meets primary efficacy
Seekingalpha · 08/16 12:42
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CANF. Analyze the recent business situations of CAN FITE BIOPHAR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CANF stock price target is 6.00 with a high estimate of 9.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 9
Institutional Holdings: 356.04K
% Owned: 1.86%
Shares Outstanding: 19.09M
TypeInstitutionsShares
Increased
1
33.68K
New
3
224.94K
Decreased
4
5
Sold Out
1
913
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Director
Ilan Cohen
Chief Executive Officer/Director
Pnina Fishman
Chief Financial Officer/Chief Operating Officer
Motti Farbstein
Director
Guy Regev
Director
Abraham Sartani
Director
Israel Shamay
No Data
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Webull offers kinds of Can Fite Biopharma Ltd stock information, including AMEX:CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.